A framework for blood biomarker discovery in MS

Read full text Summarise with VIRAT
Authors: Emma Clare Tallantyre, Sean Apap Mangion, Charlotte Elisabeth Teunissen
Cited by: 0
References: 66

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Multiple sclerosis (MS) biomarkers hold potential for improving pathophysiological understanding, diagnostics, prognostication, and treatment personalisation. Technological advances now permit detection of blood biomarkers at previously prohibitively low concentrations. Concentrations of several candidate biomarkers have been shown to correlate between blood and cerebrospinal fluid (CSF). The development of '-omics' panel-based technologies now facilitates the discovery of collections of molecules, the interdependency of which may better reflect disease heterogeneity. Neurofilament light (NfL) is the clearest example of the success of a biomarker entering the realm of clinical practice in MS, with promising developments in others such as glial fibrillary acid protein (GFAP). However, integration of new biomarkers requires standardisation of discovery and validation across the various available technologies, along with demonstration of clinical utility, to gain regulatory approval and widespread adoption. In this review, focused on blood-based biomarkers, we expand on the above discoveries, developments and trajectories, to provide a framework for understanding this crucial body of work.

Fields of Study & Subjects

Multiple Sclerosis Research Studies Metabolomics and Mass Spectrometry Studies Advanced Biosensing Techniques and Applications

Publication details

Journal / source
Multiple Sclerosis Journal
Volume
32
Issue
7
Pages
661–669
Publication date
30 March 2026
Language
EN